CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
慢性淋巴细胞白血病治疗新时代中的嵌合抗原受体-T 细胞
英文原题：Chimeric Antigen Receptor-T Cells in the Modern Era of Chronic Lymphocytic Leukemia Treatment.
查看英文原题
Chimeric Antigen Receptor-T Cells in the Modern Era of Chronic Lymphocytic Leukemia Treatment.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
靶向Bruton酪氨酸激酶（BTK）和B细胞淋巴瘤-2（BCL-2）的通路抑制剂已显著改变了初治和复发/难治性慢性淋巴细胞白血病（CLL）的治疗格局。然而，随着使用量的增加，越来越多的患者将在两种药物上出现疾病进展。这一“双重难治”患者亚群的治疗选择有限，预后较差。嵌合抗原受体（CAR）-T细胞已改变了复发/难治性B细胞恶性肿瘤的治疗。尽管CAR-T 细胞疗法最早的成功是在CLL中，但该模式的临床应用一直滞后，直到最近首个CAR-T 细胞产品获批用于CLL。在这篇综述中，我们描述了当前一线和后续治疗的选择，以及CAR-T 细胞疗法日益重要的作用和挑战所凸显的对新药未满足的需求。
展开英文摘要原文
Pathway inhibitors targeting Bruton tyrosine kinase (BTK) and B-cell lymphoma-2 (BCL-2) have dramatically changed the treatment landscape for both treatment-na ve and relapsed/refractory chronic lymphocytic leukemia (CLL).
However, with increased utilization, a growing number of patients will experience progressive disease on both agents. This subgroup of "double refractory" patients has limited treatment options and poor prognosis. Chimeric antigen receptor (CAR)-T cells have transformed the treatment of relapsed/refractory B-cell malignancies.
Although the earliest success of CAR-T cell therapy was in CLL, the clinical application of this modality has lagged until the recent approval of the first CAR-T cell product for CLL. In this review, we describe the current treatment options for upfront and subsequent therapies and the unmet need for novel agents highlighted by the burgeoning role and challenges of CAR-T cell therapy.
论文信息
- 作者
- Hatashima A、Shadman M、Raghunathan V
- 第一作者单位
- Department of Pharmacy, University of Washington, Seattle, WA 98195, USA.United States
- 通讯作者单位
- Division of Hematology and Medical Oncology, University of Washington, Seattle, WA 98195, USA.United States
- 文献类型
- 综述
- 期刊
- Cancers2025 Jan 15
- 原文标识
- PubMed 39858050 · DOI 10.3390/cancers17020268
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →